Mechanisms of Epigenetic Plasticity in PDAC
PDAC表观遗传可塑性机制
基本信息
- 批准号:10379399
- 负责人:
- 金额:$ 48.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAblationBiological ModelsBypassCharacteristicsChromatin Conformation Capture and SequencingClinicalComplexDevelopmentDisease OutcomeEpigenetic ProcessEquilibriumExtinction (Psychology)GatekeepingGenesGeneticGenetic EngineeringGenetic ScreeningGenetic TranscriptionGenomicsGrantHomeostasisHumanKRAS oncogenesisLabelLesionMaintenanceMalignant - descriptorMalignant NeoplasmsMetabolicModelingMolecularMolecular TargetMusMutationNecrosisNeoplasm MetastasisNoduleOncogenicOncoproteinsOralOutputPancreasPancreatic Ductal AdenocarcinomaPathway interactionsPharmaceutical PreparationsPopulationProteinsRefractoryRelapseReporterResearchResistanceResistance developmentRoleRouteSignal TransductionStressSystemTechniquesTherapeuticTherapeutic AgentsTimeTumor Cell Invasionaddictioncancer therapychemical geneticschromatin remodelingdriving forceeffective therapyexperimental studyflexibilityfollow-upimprovedin vivoin vivo evaluationinhibitorinsightinterestloss of functionmouse modelneoplastic cellnext generationnovel therapeutic interventiononcogene addictionpancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpredictive modelingpreventprogenitorresponsesmall moleculestemstem cellsstem-like cellsynergismtheoriestherapy resistanttranscription factortreatment strategytumortumor growthtumor microenvironmenttumor progressionvirtual
项目摘要
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly human cancers and in ~95%
of cases driven by oncogenic mutations of Kras. Unfortunately, attempts to directly inhibit
oncogenic Kras or Ras effector pathways have been largely ineffective in treating PDAC due to
the development of resistance. Yap (Yes-associated-protein), an oncogenic transcription
regulator, not only is required for PDAC progression but also confers resistance to extinction of
oncogenic Kras signaling and other therapeutic agents in advanced PDAC tumors. Using a next-
generation inducible genetic engineered mouse model, we discovered that even though PDAC
tumors rely on Yap to maintain the transcriptional output necessary for tumor growth and survival,
a subpopulation of tumor cells with stem/progenitor-like characteristics undergo epigenetic
reprogramming eventually overcoming their Yap addiction in late stage PDAC. In this grant we
propose a multi-faceted effort to elucidate the molecular/cellular drivers of adaptive
reprogramming in Yap-ablated, advanced PDAC tumors, and explore novel therapeutic strategies
to overcome resistance to Yap blockade. Furthermore, we will use an inducible genetic lineage-
tracing model to track how the cancer “stem/progenitor” niches contribute to PDAC invasion,
metastasis and resistance to Yap ablation. Together, these experiments will not only provide
critical insights into the mechanisms underlying PDAC plasticity, but also inform potential new
strategies to overcome therapeutic resistance in PDAC.
胰腺导管腺癌(PDAC)是人类最致命的癌症之一,
由Kras致癌突变驱动的病例。不幸的是,试图直接抑制
致癌的Kras或Ras效应子途径在治疗PDAC中很大程度上无效,
抵抗力的发展雅普(是相关蛋白),一种致癌转录
调节剂,不仅是PDAC进展所必需的,而且还赋予对PDAC消退的抗性。
致癌Kras信号传导和其他治疗剂在晚期PDAC肿瘤中的作用。使用下一个-
第二代诱导型基因工程小鼠模型,我们发现,即使PDAC
肿瘤依赖于雅普来维持肿瘤生长和存活所必需的转录输出,
具有干/祖细胞样特征的肿瘤细胞亚群经历表观遗传
重新编程最终在PDAC后期克服了他们的雅普成瘾。在这份协议中,我们
提出了一个多方面的努力,以阐明适应性的分子/细胞驱动因素,
在Yap消融的晚期PDAC肿瘤中进行重编程,并探索新的治疗策略
克服对雅普封锁的抵抗另外,我们会用一种诱导型基因谱系-
追踪模型以追踪癌症“干/祖细胞”小生境如何促成PDAC侵袭,
转移和对雅普消融的抗性。这些实验不仅能提供
对PDAC可塑性机制的重要见解,也为潜在的新的
克服PDAC治疗耐药性的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alessandro Gardini其他文献
Alessandro Gardini的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alessandro Gardini', 18)}}的其他基金
Role of an Integrator-EGR axis in the regulation of myeloid enhancers (Admin Supp)
Integrator-EGR 轴在骨髓增强子调节中的作用(管理补充)
- 批准号:
10007301 - 财政年份:2020
- 资助金额:
$ 48.3万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10534872 - 财政年份:2019
- 资助金额:
$ 48.3万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10310455 - 财政年份:2019
- 资助金额:
$ 48.3万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10748543 - 财政年份:2019
- 资助金额:
$ 48.3万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10536618 - 财政年份:2019
- 资助金额:
$ 48.3万 - 项目类别:
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Integrator-EGR 轴在骨髓增强子调节中的作用
- 批准号:
10064637 - 财政年份:2019
- 资助金额:
$ 48.3万 - 项目类别:
相似海外基金
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
- 批准号:
24K21101 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
- 批准号:
24K11201 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
- 批准号:
24K11281 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
- 批准号:
EP/Z001145/1 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
- 批准号:
2338890 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334777 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334775 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
- 批准号:
2334776 - 财政年份:2024
- 资助金额:
$ 48.3万 - 项目类别:
Continuing Grant
Cryo laser-ablation system (157+193nm) with 'triple-quad' plasma mass spectrometer, Cryo-LA-ICPMS/MS
带有“三重四极杆”等离子体质谱仪、Cryo-LA-ICPMS/MS 的冷冻激光烧蚀系统 (157 193nm)
- 批准号:
515081333 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Major Research Instrumentation
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
- 批准号:
2320040 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Standard Grant